Recently, Japanese experts have investigated the positive effects of the diabetes drug dapagliflozin on heart failure patients.
Cardiovascular breakdown is a condition where the heart can't siphon blood around the body appropriately.
The Japanese specialists zeroed in on the exploration of how the previously mentioned drug influences the trial of a particular biomarker, UACR (pee egg whites to creatinine proportion), in the pee.
The research was led by Dr. Fumiki Yoshihara at the National Cerebral and Cardiovascular Center in Osaka, Japan. The researchers wanted to see if dapagliflozin could improve UACR levels in patients with heart failure and type 2 diabetes.
The study included 146 patients who were given 5 mg of dapagliflozin daily for 2 years. The researchers found that the drug had no significant effect on UACR but that it was helpful in some heart-related problems.
The drug reduced the volume of the left ventricle of the heart. Because left ventricular enlargement can be a problem in terms of heart failure, In addition, patients also experienced fewer serious cardiac events, such as the need to go to the hospital in an emergency.